Thiazolidinedione analogues for the treatment of hypertension

Abstract

The present invention relates to thiazolidinedione analogues that are useful for treating hypertension, diabetes, and inflammatory diseases. Formula (I), wherein: each of R1 and R4 is independently selected from H, halo, aliphatic, and alkoxy, wherein the aliphatic and alkoxy are optionally substituted with 1-3 of halo; R2 is halo, hydroxy, or optionally substituted aliphatic, and R'2 is H, or R2 and R'2 together form oxo; R3 is H; and Ring A is a phenyl.

Description

priority claim This application claims priority to US Provisional Application 60 / 972,639, filed September 14, 2007, which is incorporated in its entirety. Technical Field of the Invention The present invention provides pharmaceutical compositions comprising selective thiazolidinedione analogs for use in the treatment and prevention of diabetes, hypertension, diabetes and inflammatory diseases and inflammatory diseases. Background technique Over the past few decades, scientists have postulated that PPARγ is the generally accepted site of action for insulin-sensitizing thiazolidinedione compounds. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear hormone receptor superfamily, are ligand-activated transcription factors that regulate gene expression. PPARs are involved in autoimmune and other diseases, namely diabetes, cardiovascular and gastrointestinal diseases, and Alzheimer's disease. PPARγ is a key regulator of adipocyte differentiation and ...

AI Technical Summary

Problems solved by technology

However, compounds involved in the activation of PPARγ also cause sodium reabsorption and other undesirable side effects

Images